UPM-Kymmene has patented a method for drying hydrogel with nanofibrillar cellulose, polyethylene glycol, and trehalose to create a freeze-dried medical aerogel. The aerogel contains specific pharmaceutical ingredients and has a low moisture content. The weight ratio of components is crucial for its effectiveness. GlobalData’s report on UPM-Kymmene gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on UPM-Kymmene, Microscale biofuel reactors was a key innovation area identified from patents. UPM-Kymmene's grant share as of January 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Freeze-dried medical aerogel with nanofibrillar cellulose and pharmaceutical ingredients
A recently granted patent (Publication Number: US11850306B2) discloses a freeze-dried medical aerogel comprising nanofibrillar cellulose, a single active pharmaceutical ingredient selected from a wide range including antibiotics, pain relievers, vitamins, and medication for various diseases, polyethylene glycol, and trehalose. The aerogel has a moisture content of 10% or less and the components are present in specific weight ratios. The active pharmaceutical ingredient content in the aerogel ranges from 0.1% to 65% (w/w).
Furthermore, the patent details the method of obtaining the freeze-dried medical aerogel, which involves providing a hydrogel with nanofibrillar cellulose, polyethylene glycol, and trehalose, mixing them, and freeze-drying the mixture. The nanofibrillar cellulose plays a crucial role as the only polymeric gel-forming material in the aerogel, with specific characteristics such as length exceeding 1 µm, a diameter smaller than 200 nm, and specific viscosity and yield stress values. The active pharmaceutical ingredient can vary and includes well-known medications like metronidazole, lidocaine, and tamoxifen, among others. This innovative aerogel formulation opens up possibilities for controlled drug delivery systems and medical applications due to its unique composition and properties outlined in the patent claims.
To know more about GlobalData’s detailed insights on UPM-Kymmene, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
